Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Suven Life Sciences's Days Payable or its related term are showing as below:
During the past 13 years, Suven Life Sciences's highest Days Payable was 48838.78. The lowest was 57.73. And the median was 1285.27.
NSE:SUVEN's Days Payable is not ranked *
in the Drug Manufacturers industry.
Industry Median: 90.28 * Ranked among companies with meaningful Days Payable only.
Suven Life Sciences's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
The historical data trend for Suven Life Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suven Life Sciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Suven Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Suven Life Sciences's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suven Life Sciences (NSE:SUVEN) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Suven Life Sciences and its competitors. Over the past decade, Suven Life Sciences' Days Payable has ranged from 57.73 to 48,838.78. According to the industry distribution chart, Suven Life Sciences ranks #999999 out of 927 companies in the Drug Manufacturers industry.
Is Suven Life Sciences' Days Payable too high?
Suven Life Sciences' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 57.73 to a high of 48,838.78. Based on the distribution chart, Suven Life Sciences ranks #999999 out of 927 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Suven Life Sciences has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Suven Life Sciences' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Suven Life Sciences ranks #999999 out of 927 companies for Days Payable. This places Suven Life Sciences in the lower half of its industry. The industry median Days Payable is 90.28. Historically, Suven Life Sciences' own Days Payable has ranged from 57.73 to 48,838.78 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.28, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Suven Life Sciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suven Life Sciences's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suven Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Suven Life Sciences (NSE:SUVEN) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹96.25, compared to a current price of ₹307.10 — trading 219.1% above its estimated fair value. The current Days Payable is 0.00. Suven Life Sciences' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Suven Life Sciences (NSE:SUVEN), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suven Life Sciences (NSE:SUVEN) Overvalued in 2026?
Based on GuruFocus' analysis, Suven Life Sciences stock appears to be overvalued.
The current stock price of ₹307.10 is trading 219.1% above its estimated GF Value™ of ₹96.25.
GuruFocus considers Suven Life Sciences to be Significantly Overvalued.
Key valuation signals for NSE:SUVEN:
Days Payable: 0.00
GF Value™: ₹96.25 vs. price of ₹307.10 (219.1% above fair value)
No single metric tells the full story. See the NSE:SUVEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.
47GF Score
Get the complete analysis for NSE:SUVEN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUVEN has been successfully added to your 
